Clinical Trial

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of…

2 months ago

ORLADEYO® (berotralstat) Approved in Peru

RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate…

2 months ago

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Late-breaking presentation shows SYFOVRE® (pegcetacoplan injection) demonstrated visual function benefit on prespecified endpoint in GALE long-term extension study WALTHAM, Mass.,…

2 months ago

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS)…

2 months ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August…

2 months ago

Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium

Oral presentation will showcase novel VCIEL scale for assessing small intestinal mucosal health in Celiac DiseaseBOCA RATON, Fla., July 09,…

2 months ago

Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr

WILMETTE, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing…

2 months ago

Preveceutical Announces Revocation of Management Cease Trade Order

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"…

2 months ago

Vectorious Medical Technologies Reports Novel Findings From VECTOR HF Trials: Self-Management of Heart Failure Patients Using Left Atrial Pressure

TEL AVIV, Israel, July 8, 2024 /PRNewswire/ -- Vectorious Medical Technologies Ltd. announces the publication of a breakthrough pilot clinical study,…

2 months ago

CBIH: Unleashing the Potential of Cannabis for Tomorrow’s Medicine

A letter from our deskHouston, Texas--(Newsfile Corp. - July 8, 2024) - Since the start of the year, Cannabis Bioscience…

2 months ago